Headlines about ProShares UltraShort Nasdaq Biotech (NASDAQ:BIS) have been trending somewhat positive this week, according to Accern Sentiment. The research group scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. ProShares UltraShort Nasdaq Biotech earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.4086029406562 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
NASDAQ BIS opened at $19.47 on Friday. ProShares UltraShort Nasdaq Biotech has a 12 month low of $17.52 and a 12 month high of $25.21.
ProShares UltraShort Nasdaq Biotech Company Profile
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.
Receive News & Ratings for ProShares UltraShort Nasdaq Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares UltraShort Nasdaq Biotech and related companies with MarketBeat.com's FREE daily email newsletter.